Gilead Emtriva Marketing For HIV Will Highlight Long Intracellular Half-Life
Executive Summary
Gilead Sciences' is highlighting Emtriva's long intracellular half-life as a distinguishing feature in the nucleoside reverse transcriptase inhibitor market for HIV therapy